2014

1. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

   Bone Marrow Transplantation, Vol. 49, Núm. 5, pp. 684-690

2. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome

   Leukemia Research, Vol. 38, Núm. 5, pp. 551-556

3. Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease

   Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 10, pp. 1580-1585